Better tolerability of the applied treatment was demonstrated in the North American Brain Tumour Consortium Study in the case of pazopanib, which is a second-generation multi-targeted tyrosine kinase inhibitor with activity on several receptors including VEGFR1, VEGFR2, and VEGFR. The gene discussed is KDR; the disease is brain neoplasm.